LANSING, Mich., May 5, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Kraig"), the leading developer of advanced spider silk based fibers, announced today that Warwick Mills, Inc. ("Warwick"), a leader in the engineering and development of advanced technical textiles and protective materials, is preparing to weave the first textiles with Kraig's Monster Silk™ recombinant spider silk. This is part of Kraig's collaborative development initiative of advanced spider silk based textiles.
Kraig previously shipped Monster Silk™ yarn to Warwick, which after studying the material, requested that it be processed to additional specifications. The material was shipped back to Kraig and then studied by a silk spinning expert who analyzed the fibers. The fibers were then processed according to the directions and specifications of the spinning expert. Recently, Kraig received the reprocessed Monster Silk™ and shipped the material to Warwick. Warwick is now testing and analyzing Kraig's Monster Silk™ recombinant spider silk and determining the best ply and cord twisting for yarn optimization in preparation for creating sample textiles.
"We appreciate and respect the fact that Warwick asked us to reprocess the material instead of just moving forward at full speed with weaving or knitting," said Kraig CEO and founder, Kim Thompson. "Warwick has taken the time to do this right. As a result, the development of Monster Silk™ based textiles is at an exciting stage, Warwick is preparing to create the first Monster Silk™ textiles."
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc